1 / 6

Vicki Ehrich Chief Operating Officer PIASA 25 July 2007

Balancing Regulation Against Access to Innovative Pharmaceuticals. Vicki Ehrich Chief Operating Officer PIASA 25 July 2007. Benefits of local industry investment and presence. Registration and ‘early’ launch of new medicines Local investment in education and training

vala
Download Presentation

Vicki Ehrich Chief Operating Officer PIASA 25 July 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Balancing Regulation Against Access to Innovative Pharmaceuticals Vicki Ehrich Chief Operating Officer PIASA 25 July 2007

  2. Benefits of local industry investment and presence • Registration and ‘early’ launch of new medicines • Local investment in education and training • Local investment in clinical research • Industry investment in therapeutic areas • Local supply to State Sector • Skills and technology transfer • Pipeline for generic medicines

  3. Attracting Pharmaceutical Investment • Financial Incentives • Stimulation of Innovation • Secure IP Framework • Efficient regulatory framework • Large volume / funded market • Access to high level skills pool

  4. IP Framework • Bolar provision • Data protection • Compulsory licensing/parallel imports • Voluntary licensing

  5. Large volume / funded market • ‹ 1% world market • No developed regional market • No regulatory harmonization • Stagnant private market • Low value government market • Little access to donor demand • Global competitiveness? • Export incentives?

  6. Members of PIASA Abbott Laboratories South Africa (Pty) Ltd Adcock Ingram Healthcare (Pty) Ltd Alcon Laboratories (Pty) Ltd Altana Madaus (Pty) Ltd Astra Zeneca Pharmaceuticals (Pty) Ltd Bayer Schering Pharma (Pty) Ltd Boehringer Ingelheim (Pty) Ltd Bristol-Myers Squibb (Pty) Ltd Galderma Laboratories (Pty) Ltd GE Health (Pty) Ltd Genop Healthcare (Pty) Ltd GlaxoSmithKline South Africa (Pty) Ltd iNova Pharmaceuticals (Pty) Ltd Janssen-Cilag (Pty) Ltd Key Oncologics (Pty) Ltd Merck (Pty) Ltd Novo-Nordisk (Pty) Ltd Schering-Plough (Pty) Ltd Sekunjalo Health Care Ltd Servier Laboratories SA Pty) Ltd Solvay Pharma (Pty) Ltd Stiefel Laboratories (Pty) Ltd Tyco Healthcare (Pty) Ltd UCB Pharma South Africa (Pty) Ltd Wyeth South Africa (Pty) Ltd

More Related